Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight Ponders The Meaning Of The Best Year For Biotech IPOs Since 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financings by Regulus, Aragon, Antabio and Asceneuron.

You may also be interested in...



With New Data For A Drug In Dispute, Aragon Raises $50 Million

The San Diego biotech’s Series D round will support continued development of a drug that Medivation claims was included in the same license that covered the recently approved prostate cancer drug Xtandi.

More And Better Biotech IPOs, But Step-Ups Still Lag

Higher valuations, better quality companies, improved aftermarket performance and a broadening investor pool are all conspiring to advance the state of biotech IPOs. But VCs continue to see little step-up at IPO.

Merck KGAA Begins Transformation Effort By Closing Geneva Site

The efficiency program outlined by the German pharma in February will mean elimination of 500 Merck Serono staff in Switzerland, with another 750 employees being redeployed to Germany, China or the U.S.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel